Do acetyl salicylic acid and terbutaline in combination increase the probability of a clinical pregnancy in patients undergoing IVF/ICSI?

J Obstet Gynaecol. 2012 Nov;32(8):786-9. doi: 10.3109/01443615.2012.717988.

Abstract

The present study investigated if acetyl salicylic acid (ASA) and terbutaline in combination increased the clinical pregnancy rate in patients undergoing in vitro fertilisation (IVF)/intra-cytoplasmic sperm injection (ICSI). A randomised controlled trial was designed, in which 167 patients were randomised to taking ASA for 9 weeks after embryo transfer and terbutaline around the time of embryo transfer as adjuvant medication. A total of 112 patients were randomised to no adjuvant medication. The clinical pregnancy rate per controlled ovarian hyperstimulation was 30.5% in the intervention group and 42.0% in the control group. This difference was not statistically significant, and we conclude that ASA and terbutaline in combination do not increase the clinical pregnancy rate after IVF/ICSI treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / therapeutic use*
  • Drug Therapy, Combination
  • Embryo Transfer
  • Female
  • Fertilization in Vitro
  • Humans
  • Intention to Treat Analysis
  • Pregnancy
  • Pregnancy Rate
  • Sperm Injections, Intracytoplasmic*
  • Terbutaline / therapeutic use*

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Anti-Inflammatory Agents, Non-Steroidal
  • Terbutaline
  • Aspirin